DDInter342 DDInter1376
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stavudine
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Abatacept
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Tildrakizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Stavudine
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Certolizumab pegol may lead to a major life threatening interaction when taken with Abatacept
Certolizumab pegol may lead to a major life threatening interaction when taken with Tildrakizumab